19
total announcements
SAILIFE.NS · 15 min delayed
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 27th Annual General Meeting to be held through Video Conference/OAVM on September 17, 2026.
Sai Life Sciences Limited
Sai Life Sciences Limited has sent web link letters to shareholders whose email addresses are not registered with the company, registrar, or depository participant, containing the navigation path to access the Integrated Annual Report for FY 2025-26.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 17, 2026.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 27th Annual General Meeting (AGM) to be held on September 17, 2026, through video conference.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange regarding 'Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.' The 27th AGM will be held on September 17, 2026, through Video Conferencing, and members can exercise their right to vote electronically on all the resolutions set forth in the notice of 27th AGM.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange about the Transcript of the Earnings conference call organized on 07 August 2026, post declaration of the Un-audited Financial Results of the Company for the quarter ended 30 June 2026.
Sai Life Sciences Limited
Sai Life Sciences Limited has published its un-audited financial results for the quarter ended June 30, 2026, which show a net profit of ₹291.0 crore, a 24% decrease from the same quarter last year. The company's total income from operations was ₹559.9 crore, a 16% decrease from the same quarter last year. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 6, 2026.
Sai Life Sciences Limited
Crisil Ratings Limited, the monitoring agency, has submitted a report on the utilization of proceeds from Sai Life Sciences Limited's Initial Public Offer (IPO) for the quarter ended June 30, 2026. The report states that there are no deviations from the objects of the issue.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange about the link of recording of earnings call for the un-audited financial results of the company for the quarter ended on 30 June 2026.
Sai Life Sciences Limited
Sai Life Sciences Limited has released its Q1FY27 investor presentation, highlighting a 12% YoY revenue growth to ₹554 crore, with CRO business growing 24% YoY and CDMO business growing 15% YoY. The company has a strong pipeline with 33 active commercial molecules and 14 late-phase molecules. The company has also achieved an EcoVadis Platinum Rating 2026 and operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange regarding allotment of 18,700 securities pursuant to ESOP/ESPS at its meeting held on August 06, 2026.
Sai Life Sciences Limited
Sai Life Sciences Limited has reported strong financial results for the first quarter ended June 30, 2026, with revenue up 12% year-on-year and net profit up 22% year-on-year.
Sai Life Sciences Limited
Sai Life Sciences Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, showing revenue from operations at Rs. 5,467.29 million and profit for the period at Rs. 713.39 million.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange about Schedule of Analyst/Institutional Investors meet to be held on 13 August 2026 & 14 August 2026 at Singapore.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange about the schedule of an earnings conference call to discuss the Un Audited Financial Results of the Company for the Quarter ended 30 June 2026.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange regarding the allotment of 8,900 shares under the Employees Stock Option Plan 2008 (ESOP 2008).
Sai Life Sciences Limited
Sai Life Sciences Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, regarding the details of securities dematerialized/rematerialized during the period.
Sai Life Sciences Limited
Sai Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Sai Life Sciences Limited
Sai Life Sciences Limited has allotted 170,501 fully paid-up equity shares of Re. 1/- each to employees who exercised options granted under its ESOP 2008 and MESOP 2018 schemes. This allotment, approved on June 22, 2026, increases the total issued shares to 21,22,86,016. The shares were issued at varying exercise prices of Rs. 188.90, Rs. 23.30, and Rs. 127.30, resulting in a minor capital inflow for the company.